Nurse-Developed Algorithm Helps Identify Pneumocystis Pneumonia Risk
The nurse care pathway outlines best practices for monitoring, and responding to, pneumocystis jirovecii pneumonia risk in patients with multiple myeloma receiving novel, high-risk therapies.
Pegfilgrastim Plus Plinabulin May Help Mitigate Neutropenia Risk in Patients With Myeloma
Adding plinabulin to prophylactic pegfilgrastim and antibiotics may help prevent nonengraftment–related febrile neutropenia.
Real-world Data Highlight Daratumumab Compliance Rates in MM Patients
Findings of a retrospective analysis of patients with multiple myeloma showed that the median duration of treatment with daratumumab was 16.6 months.
Optimizing QOL Assessments Requires Multiple Patient-Reported Outcomes Measures
There is no one-size-fits-all approach to establishing patient-reported outcome measures, according to Hayley Beer, RN.
Ocular Visits Are a Necessity for Patients With Multiple Myeloma Who Receive Belantamab Mafodotin
A post hoc analysis from the phase 2 DREAMM-2 trial highlighted the ocular toxicity risks that belantamab mafodotin poses for patients with multiple myeloma.
Verina Underscores Best Nursing Practices With Targeted Therapies in Multiple Myeloma
Daniel J. Verina, DNP, RN, MSN, ACNP-BC, highlights optimal adverse event management with CD38- and SLAM-F7-directed monoclonal antibodies, XPO-1 inhibitors, and CAR T-cell therapies.
Oral and Dermatologic Toxicities Associated With Talquetamab Can Be Mitigated With Nurse Intervention
Through patient education tactics, oncology nurses can help patients with multiple myeloma mitigate the oral and dermatologic toxicities associated with talquetamab.
Minimal Residual Disease May Anticipate Outcomes in Myeloma Following Stem Cell Transplant
Patients with myeloma and a negative MRD may be at a reduced risk of mortality and other progression-free survival events.
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo
